Published in Neurourol Urodyn on September 29, 2010
Preventing UTIs in Chronic Neurogenic Bladder Dysfunction (Mix Methods) (PReSuTINeB) | NCT02591901
Quality improvement in neurology: Multiple sclerosis quality measures: Executive summary. Neurology (2015) 2.08
Characteristics of persons with overactive bladder of presumed neurologic origin: results from the Boston Area Community Health (BACH) survey. Neurourol Urodyn (2012) 1.38
Neurogenic bladder. Adv Urol (2012) 0.95
An exploratory, placebo-controlled, dose-response study of the efficacy and safety of onabotulinumtoxinA in spinal cord injury patients with urinary incontinence due to neurogenic detrusor overactivity. World J Urol (2012) 0.93
Health-related quality of life and economic impact of urinary incontinence due to detrusor overactivity associated with a neurologic condition: a systematic review. Health Qual Life Outcomes (2013) 0.91
Use of botulinum toxin in individuals with neurogenic detrusor overactivity: state of the art review. J Spinal Cord Med (2013) 0.89
Neurogenic bladder in spinal cord injury patients. Res Rep Urol (2015) 0.82
Neurogenic Causes of Detrusor Underactivity. Curr Bladder Dysfunct Rep (2015) 0.81
Bladder reinnervation using a primarily motor donor nerve (femoral nerve branches) is functionally superior to using a primarily sensory donor nerve (genitofemoral nerve). J Urol (2014) 0.81
Botulinum toxin in spinal cord injury patients with neurogenic detrusor overactivity. J Exerc Rehabil (2016) 0.81
Urinary tract infection in the neurogenic bladder. Transl Androl Urol (2016) 0.81
Hospitalization rates and discharge status in multiple sclerosis. Mult Scler Int (2013) 0.80
Central neuropathic pain in a patient with multiple sclerosis treated successfully with topical amitriptyline. Case Rep Med (2012) 0.79
Congenital causes of neurogenic bladder and the transition to adult care. Transl Androl Urol (2016) 0.79
Urological Surveillance and Medical Complications after Spinal Cord Injury in the United States. Urology (2015) 0.78
Cost-effectiveness analysis of onabotulinumtoxinA (BOTOX(®)) for the management of urinary incontinence in adults with neurogenic detrusor overactivity: a UK perspective. Pharmacoeconomics (2015) 0.78
Bibliometric profile of neurogenic bladder in the literature: a 20-year bibliometric analysis. Neural Regen Res (2015) 0.77
S-Nitrosoglutathione protects the spinal bladder: novel therapeutic approach to post-spinal cord injury bladder remodeling. Neurourol Urodyn (2014) 0.76
Efficacy and safety of ginger-salt-indirect moxibustion for urge urinary incontinence after stroke: protocol for a pilot multicentre randomised controlled trial. BMJ Open (2014) 0.76
Risk factors of urethral diverticula in male patients with spinal cord injury. Spinal Cord (2015) 0.75
Optimal bladder diary duration for patients with suprapontine neurogenic lower urinary tract dysfunction. Int Braz J Urol (2016) 0.75
Lower urinary tract symptoms: thinking beyond the urinary tract. BMJ Case Rep (2014) 0.75
Efficacy and Adverse Events Associated With Use of OnabotulinumtoxinA for Treatment of Neurogenic Detrusor Overactivity: A Meta-Analysis. Int Neurourol J (2017) 0.75
Pregnancy outcomes following exposure to onabotulinumtoxinA. Pharmacoepidemiol Drug Saf (2015) 0.75
Antibiotic prophylaxis may not be necessary in patients with asymptomatic bacteriuria undergoing intradetrusor onabotulinumtoxinA injections for neurogenic detrusor overactivity. Sci Rep (2016) 0.75
Not all neurogenic bladders are the same: a proposal for a new neurogenic bladder classification system. Transl Androl Urol (2016) 0.75
Real life persistence rate with antimuscarinic treatment in patients with idiopathic or neurogenic overactive bladder: a prospective cohort study with solifenacin. BMC Urol (2017) 0.75
Can We Further Improve the Quality of Nephro-Urological Care in Children with Myelomeningocele? Int J Environ Res Public Health (2016) 0.75
The Worldwide Economic Impact of Neurogenic Bladder. Curr Bladder Dysfunct Rep (2015) 0.75
Patients With Neurogenic Lower Urinary Tract Dysfunction Following Spinal Cord Injury Are at Increased Risk of Developing Type 2 Diabetes Mellitus: A Population-Based Cohort Study. Medicine (Baltimore) (2016) 0.75
A home-based comprehensive care model in patients with Multiple Sclerosis: A study pre-protocol. F1000Res (2015) 0.75
Uremic encephalopathy with isolated brainstem involvement revealed by magnetic resonance image: a case report. BMC Neurol (2017) 0.75
Changes in Management of Poorly Compliant Bladder in Botulinum Toxin A Era. Curr Urol Rep (2017) 0.75
Recurrent urinary tract infections in patients with incomplete bladder emptying: is there a role for intravesical therapy? Transl Androl Urol (2017) 0.75
Study protocol: patient reported outcomes for bladder management strategies in spinal cord injury. BMC Urol (2017) 0.75
Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol (2007) 6.73
Best practice policy statement on urologic surgery antimicrobial prophylaxis. J Urol (2008) 4.90
American Urological Association guideline on the management of priapism. J Urol (2003) 3.77
AUA guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. J Urol (2011) 3.00
Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol (2005) 2.92
Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc (2003) 2.75
Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol (2010) 2.68
Risk of impaired renal function after colonoscopy: a cohort study in patients receiving either oral sodium phosphate or polyethylene glycol. Am J Gastroenterol (2007) 2.44
Guidelines for submitting adverse event reports for publication. Drug Saf (2007) 2.38
Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol (2011) 2.37
Immediate effects of the initial FDA notification on the use of surgical mesh for pelvic organ prolapse surgery in medicare beneficiaries. Neurourol Urodyn (2012) 2.35
Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J Urol (2012) 2.29
A contemporary assessment of nocturia: definition, epidemiology, pathophysiology, and management--a systematic review and meta-analysis. Eur Urol (2012) 1.81
A refocus on the bladder as the originator of storage lower urinary tract symptoms: a systematic review of the latest literature. Eur Urol (2009) 1.76
Lower urinary tract symptoms revisited: a broader clinical perspective. Eur Urol (2008) 1.62
A randomized double-blind placebo-controlled phase 2 dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia. Eur Urol (2012) 1.61
Nocturia Think Tank: focus on nocturnal polyuria: ICI-RS 2011. Neurourol Urodyn (2012) 1.56
Chapter 1: The management of erectile dysfunction: an AUA update. J Urol (2005) 1.55
The New England Research Institutes, Inc. (NERI) Nocturia Advisory Conference 2012: focus on outcomes of therapy. BJU Int (2013) 1.52
Urodynamic studies in adults: AUA/SUFU guideline. J Urol (2012) 1.51
Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada. J Clin Psychiatry (2004) 1.48
Histologic comparison of pubovaginal sling graft materials: a comparative study. Urology (2008) 1.48
Risk factors for adverse events in analgesic drug users: results from the PAIN study. Pharmacoepidemiol Drug Saf (2003) 1.47
OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol (2012) 1.46
Overactive bladder: evaluation and management in primary care. Cleve Clin J Med (2005) 1.45
Increasing rates of breast cancer and cardiac surveillance among high-risk survivors of childhood Hodgkin lymphoma following a mailed, one-page survivorship care plan. Pediatr Blood Cancer (2010) 1.44
Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol (2007) 1.40
A randomized, controlled clinical trial of a novel intravesical pressure attenuation device for the treatment of stress urinary incontinence. J Urol (2013) 1.38
Early results of pubovaginal sling lysis by midline sling incision. Urology (2002) 1.37
Chronic obstructive pulmonary disease severity and cardiovascular outcomes. Eur J Epidemiol (2006) 1.28
AUA guideline on the pharmacologic management of premature ejaculation. J Urol (2004) 1.28
Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. J Urol (2007) 1.27
Erectile function outcome reporting after clinically localized prostate cancer treatment. J Urol (2007) 1.25
Guidelines for submitting adverse event reports for publication. Pharmacoepidemiol Drug Saf (2007) 1.23
Porcine dermis interposition graft for repair of high grade anterior compartment defects with or without concomitant pelvic organ prolapse procedures. J Urol (2004) 1.21
Approach to management of iatrogenic foreign bodies of the lower urinary tract following reconstructive pelvic surgery. J Urol (2012) 1.19
Urgency assessment in the evaluation of overactive bladder (OAB). Neurourol Urodyn (2008) 1.14
Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study. J Urol (2009) 1.11
Hospitalized cardiovascular diseases in neovascular age-related macular degeneration. Arch Ophthalmol (2008) 1.07
Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxinA in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder. Neurourol Urodyn (2011) 1.06
Impact of cisapride label changes on codispensing of contraindicated medications. Pharmacoepidemiol Drug Saf (2003) 1.04
Epidemiology of stress urinary incontinence in women. Curr Urol Rep (2011) 1.02
Patterns and predictors of urodynamics use in the United States. J Urol (2012) 1.02
Agitation and depression in frail nursing home elderly patients with dementia: treatment characteristics and service use. Am J Geriatr Psychiatry (2003) 1.01
Transdermal delivery of drugs for urologic applications: basic principles and applications. Urology (2006) 1.01
Obturator foramen dissection for excision of symptomatic transobturator mesh. J Urol (2012) 0.98
Risk of further decline in renal function after the use of oral sodium phosphate or polyethylene glycol in patients with a preexisting glomerular filtration rate below 60 ml/min. Am J Gastroenterol (2008) 0.98
Role of nicotinic and estrogen signaling during experimental acute and chronic bladder inflammation. Am J Pathol (2007) 0.98
Urethral injections for female stress incontinence. BJU Int (2006) 0.97
Development and evaluation of an interactive CD-ROM for children with leukemia and their families. Patient Educ Couns (2002) 0.97
Histopathological evaluation of the uterosacral ligament: is this a dependable structure for pelvic reconstruction? BJU Int (2006) 0.97
The evaluation and treatment of nocturia: a consensus statement. BJU Int (2011) 0.97
Removal of transobturator midurethral sling for refractory thigh pain. Urology (2008) 0.96
Genitourinary fistula experience in Sierra Leone: review of 505 cases. J Urol (2009) 0.95
Long-term efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: an interim analysis. Urology (2013) 0.93
Sling failures: what's next? Curr Urol Rep (2004) 0.92
Five-year cost analysis of intra-detrusor injection of botulinum toxin type A and augmentation cystoplasty for refractory neurogenic detrusor overactivity. World J Urol (2010) 0.92
The evolution of obstruction induced overactive bladder symptoms following urethrolysis for female bladder outlet obstruction. J Urol (2008) 0.91
Diagnosis and management of outlet obstruction in the female. Curr Opin Urol (2008) 0.91
Treatment success for overactive bladder with urinary urge incontinence refractory to oral antimuscarinics: a review of published evidence. BMC Urol (2009) 0.91
Is there an association between hypothyroidism and open-angle glaucoma in an elderly population? An epidemiologic study. Ophthalmology (2008) 0.90
The Ribavirin Pregnancy Registry: Findings after 5 years of enrollment, 2003-2009. Birth Defects Res A Clin Mol Teratol (2010) 0.90
Encapsulation of a porcine dermis pubovaginal sling. J Urol (2003) 0.90
Are patient symptoms predictive of the diagnostic and/or therapeutic value of hydrodistention? Neurourol Urodyn (2005) 0.89
Biocompatibility assessment of synthetic sling materials for female stress urinary incontinence. J Urol (2007) 0.87
Pubovaginal sling and pelvic prolapse repair in women with occult stress urinary incontinence: effect on postoperative emptying and voiding symptoms. Urology (2002) 0.87
OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity. Neurourol Urodyn (2013) 0.87
Urodynamic effects of once-daily tadalafil in men with LUTS secondary to clinical BPH. Curr Urol Rep (2010) 0.87
Do the urinary bladder and large bowel interact, in sickness or in health? ICI-RS 2011. Neurourol Urodyn (2012) 0.87
Nicotinic signaling ameliorates acute bladder inflammation induced by protamine sulfate or cyclophosphamide. J Urol (2008) 0.86
Vaginal mesh update. Curr Opin Urol (2012) 0.86
The use of a multidisciplinary morbidity and mortality conference to incorporate ACGME general competencies. J Surg Educ (2011) 0.86
Vesicovaginal fistula following a transobturator midurethral sling procedure. Int Urogynecol J Pelvic Floor Dysfunct (2006) 0.86
Risk of significant infection in rheumatoid arthritis patients switching anti-tumor necrosis factor-α drugs. Semin Arthritis Rheum (2012) 0.85
Effectiveness of rosuvastatin compared to other statins for the prevention of cardiovascular events-a cohort study in 395 039 patients from clinical practice. Pharmacoepidemiol Drug Saf (2009) 0.85
Pelvic organ prolapse (POP) surgery: the evidence for the repairs. BJU Int (2011) 0.84
Repeat urethrolysis after failed urethrolysis for iatrogenic obstruction. J Urol (2003) 0.84
Analysis of patient and technical factors associated with midurethral sling mesh exposure and perforation. Int J Urol (2014) 0.83
Management of obstructive voiding dysfunction after incontinence surgery: lessons learned. Urology (2003) 0.83
Efficacy and safety of extended release oxybutynin for the treatment of urge incontinence: an analysis of data from 3 flexible dosing studies. J Urol (2005) 0.83
The impact of the overactive bladder syndrome on sexual function: a preliminary report from the Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin trial. Am J Obstet Gynecol (2006) 0.83
Prevalence of pediatric dyslipidemia: comparison of a population-based claims database to national surveys. Pharmacoepidemiol Drug Saf (2010) 0.83
Urethral bulking: a urology perspective. Urol Clin North Am (2012) 0.82
Extended-release formulations of oxybutynin and tolterodine exhibit similar central nervous system tolerability profiles: a subanalysis of data from the OPERA trial. Am J Obstet Gynecol (2005) 0.82
Effect of antacid on the pharmacokinetics of extended-release formulations of tolterodine and oxybutynin. Clin Pharmacokinet (2004) 0.82
Management of refractory urinary urge incontinence following urogynecological surgery with sacral neuromodulation. Neurourol Urodyn (2007) 0.82
Management of overactive bladder with transdermal oxybutynin. Rev Urol (2006) 0.81
Beyond collagen: injectable therapies for the treatment of female stress urinary incontinence in the new millennium. Urol Clin North Am (2002) 0.81
Hospitalized cardiovascular events in patients with diabetic macular edema. BMC Ophthalmol (2012) 0.81